Entera Bio Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Miranda J. Toledano
- Full Time Employees
- 21
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Kiryat Hadassah Minrav Building Jerusalem JM Israel 9112002
- IPO Date
- Jun 28, 2018
- CIK
- 0001638097
- Website
- enterabio.com
- Similar Companies
- Business
- Entera Bio Ltd. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of orally delivered large molecule therapeutics targeting unmet medical needs. The company’s core products include oral peptide and protein replacement therapies primarily based on its proprietary N-Tab platform, which enhances the stabilization and systemic absorption of peptides in the gastrointestinal tract. Key product candidates include EB613 and EB612, oral formulations of human parathyroid hormone (PTH 1-34) designed for the treatment of osteoporosis and hypoparathyroidism, respectively. Entera is also developing the first oral oxyntomodulin tablet for obesity treatment and an oral GLP-2 peptide tablet for rare malabsorption conditions like short bowel syndrome, in collaboration with OPKO Biologics. The company’s products focus on transforming therapies traditionally administered by injection into convenient once-daily oral tablets to improve patient adherence and outcomes. Entera Bio operates globally with headquarters in Jerusalem, Israel, and addresses chronic conditions with significant unmet medical demand in metabolic bone disease, endocrine disorders, obesity, and intestinal malabsorption. Founded in 2012, the company is driven by a team of industry experts in drug development and oral peptide delivery. Recent major developments include a strategic research collaboration with OPKO Biologics initiated in 2023 to develop oral peptide tablet formulations for obesity and intestinal malabsorption, leveraging OPKO’s proprietary long-acting peptides and Entera’s oral delivery technology. Throughout 2025, Entera has reported positive clinical data supporting its oral GLP-2 treatment for short bowel syndrome and EB613 for osteoporosis, highlighting progress in its development pipeline for oral peptide therapeutics. The company also attracted increased investment interest with a notable acquisition of shares by Knoll Capital Management in late 2024, reflecting growing confidence in its clinical and technological prospects. Entera Bio maintains a strong intellectual property position with numerous patents and pending applications related to its oral delivery platform and peptide formulations. Its business model focuses on innovative oral therapies to replace injectable treatments, targeting cost, convenience, and compliance challenges in healthcare. The company’s advances embody a strategic shift towards delivering first-in-class oral peptide therapeutics aimed at improving the standard of care for chronic diseases that conventionally rely on injectable biologics. This comprehensive profile outlines Entera Bio’s specialized biopharmaceutical activities, advanced product pipeline, recent strategic collaborations, and clinical progress as of late 2025. The company remains headquartered in Jerusalem, Israel, serving a global market with products designed to enhance patient quality of life through oral peptide therapeutic innovation.
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement
Entera Announces Second Quarter 2026 Financial Results and Business Updates
Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know
Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity